Ace the PCCN Exam 2026 – Elevate Your Progressive Care Nursing Game!

The correct answer is that aspirin inhibits the release of thromboxane A2. Aspirin functions as an antiplatelet medication primarily through its action on cyclooxygenase (COX) enzymes, particularly COX-1. By inhibiting these enzymes, aspirin reduces the synthesis of thromboxane A2, a potent promoter of platelet aggregation and vasoconstriction. Thromboxane A2 plays a crucial role in the formation of blood clots; thus, by decreasing its levels, aspirin effectively reduces the likelihood of thrombus formation and helps in the management of various cardiovascular conditions.

The other options do not accurately reflect the primary action of aspirin. Nitric oxide is a vasodilator produced by endothelial cells and not inhibited by aspirin. Tissue necrosis is the result of various pathological processes, and while aspirin can impact overall inflammation, it does not specifically inhibit tissue necrosis. Lastly, while aspirin does reduce platelet activity as a result of inhibiting thromboxane A2, the primary compound that is directly inhibited is thromboxane A2 itself. Understanding this mechanism is critical for healthcare professionals involved in the management of patients at risk for thrombotic events.